RayKnowChina Research Map
Shortlist0

Jiangnan University

江南大学

WuxiUniversity or health system

Hospitals that carry this university's name, added together, plus papers and trials that name only the university.

Research activity, not treatment quality. Not medical advice. How this works

Nasopharyngeal carcinoma

鼻咽癌
0.5%Leads under 1 in 100 of China's research papers on NPC

Led 11 of 2,375 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (23.4%).

Run this PubMed search

Open trials led
0
Research papers it led
11
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.3%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 3320242025: 222025
ThemesImaging & AIRadiotherapy techniqueRecurrent / metastatic disease

Hospitals counted here

  1. Affiliated Hospital of Jiangnan University11

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Oesophageal squamous cell carcinoma

食管鳞状细胞癌
0.2%Leads under 1 in 100 of China's research papers on ESCC New since 2021

Led 6 of 2,923 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (6.9%).

Run this PubMed search

Open trials led
0
Research papers it led
6
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.1%
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 1120242025: 222025
ThemesImaging & AIRadiotherapyMolecular markers & genomics

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. Affiliated Hospital of Jiangnan University6

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Preoperative Diagnostic Value of Spectral CT for Predicting Perineural Invasion in Esophageal Cancer.2025Cancer medicineFree full text
  2. Association of preoperative muscle-adipose index measured by computed tomography with survival in patients with esophageal squamous cell carcinoma.2024World journal of surgical oncologyFree full text
  3. TBX18 knockdown sensitizes esophageal squamous cell carcinoma to radiotherapy by blocking the CHN1/RhoA axis.2023Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  4. Hsa_circ_0049271 Facilitates Esophageal Squamous Cell Carcinoma Progression and Cisplatin Resistance by Enhancing Cellular Senescence via miR-455-5p/ETS1.2025Journal of biochemical and molecular toxicology
  5. CircFNDC3B knockdown restrains the progression of oesophageal squamous cell carcinoma through miR-214-3p/CDC25A axis.2022Clinical and experimental pharmacology & physiology
Trials on ClinicalTrials.gov5
  1. Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell CarcinomaCompletedNCT04732494Study sitePhase 2Start 2021-03
  2. Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014).TerminatedNCT04949256Study sitePhase 3Start 2021-07
  3. A Study of Atezolizumab Plus Tiragolumab in Combination With Paclitaxel and Cisplatin Compared With Paclitaxel and Cisplatin as First-Line Treatment in Participants With Unresectable Locally Advanced, Unresectable Recurrent, or Metastatic Esophageal CarcinomaCompletedNCT04540211Study sitePhase 3Start 2020-10
  4. A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell CarcinomaCompletedNCT03783442Study sitePhase 3Start 2018-12
  5. Nimotuzumab in Combined With Paclitaxel and Cisplatin for Treatment of Metastatic Esophageal Squamous Cell CarcinomaStatus unknownNCT02611700Study sitePhase 3Start 2015-11

PubMed searchClinicalTrials.gov

Hepatocellular carcinoma

肝细胞癌
0.2%Leads under 1 in 100 of China's research papers on HCC

Led 36 of 14,765 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (5.5%).

Run this PubMed search

Open trials led
0
Research papers it led
36
Trials it led
1
Share of China's trials
0.07%
Share of the world's papers
0.1%
Papers led per year
2021: 0020212022: 0020222023: 3320232024: 0020242025: 222025
ThemesRecurrence & prognosisImaging, AI & early detectionImmunotherapy & targeted drugs

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. Affiliated Hospital of Jiangnan University19
  2. Affiliated Children's Hospital of Jiangnan University Counted in the group total3

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Stomach cancer

胃癌
0.4%Leads under 1 in 100 of China's research papers on Stomach cancer

Led 37 of 9,782 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (3.9%).

Run this PubMed search

Open trials led
2
Research papers it led
37
Trials it led
3
Share of China's trials
0.2%
Share of the world's papers
0.2%
Papers led per year
2021: 1120212022: 0020222023: 1120232024: 0020242025: 222025
ThemesImaging & AIPeritoneal spread & advanced diseaseChemotherapy & combined treatment

Hospitals counted here

  1. Affiliated Hospital of Jiangnan University29
  2. Jiangnan University Affiliated Hospital1
  3. Affiliated Children's Hospital of Jiangnan University Counted in the group total1
  4. People's Hospital, Jiangnan University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Prediction of response to neoadjuvant chemotherapy in advanced gastric cancer: A radiomics nomogram analysis based on CT images and clinicopathological features.2023Journal of X-ray science and technologyRCT
  2. Preoperative prediction for lauren type of gastric cancer: A radiomics nomogram analysis based on CT images and clinical features.2021Journal of X-ray science and technologyRCT
  3. The added value of intratumoral and peritumoral radiomic scores based on iodine density map for preoperative prediction of lymphovascular invasion in patients with gastric adenocarcinoma: a two-center study.2026Abdominal radiology (New York)
  4. Predictive values of preoperative geriatric nutritional risk index and systemic immune-inflammation index for postoperative complications and 5-year overall survival after curative resection in elderly gastric cancer pat2025Physiology international
  5. The Association Between IL-8 Gene Polymorphisms and the Risk of Several Types of Cancer, Especially in Gastric Cancer.2025Cancer reports (Hoboken, N.J.)Free full text
Trials on ClinicalTrials.gov6
  1. PET Image Exploration of 89Zr-labeled Antibody Fragments Targeting HER2 in Patients With Malignant TumorsEnrolling by invitationNCT07023848Lead sponsorEarly phase 1Start 2025-07
  2. The Exploration of Novel Radionuclide-labeled HER2-targeting Antibodies in the Diagnosis of HER2-positive MalignanciesEnrolling by invitationNCT07023861Lead sponsorEarly phase 1Start 2025-07
  3. A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid TumorsRecruitingNCT05150691Study sitePhase 1/Phase 2Start 2022-01
  4. Polaprezinc Treatment for Enzalutamide- or Abiraterone-resistant CRPCCompletedNCT05549778Lead sponsorPhase 1/Phase 2Start 2021-01
  5. Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) OverexpressionCompletedNCT05052801Study sitePhase 3Start 2022-03
  6. Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.TerminatedNCT05111626Study sitePhase 3Start 2022-03

PubMed searchClinicalTrials.gov

Osteosarcoma

骨肉瘤
0.1%Leads under 1 in 100 of China's research papers on Osteosarcoma

Led 3 of 2,257 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.3%).

Run this PubMed search

Open trials led
0
Research papers it led
3
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.06%
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 0020242025: 002025

Hospitals counted here

  1. Wuxi Children's Hospital1
  2. Affiliated Hospital of Jiangnan University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Neuroblastoma

神经母细胞瘤
0.2%Leads under 1 in 100 of China's research papers on Neuroblastoma New since 2021

Led 2 of 1,132 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.8%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.05%
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 0020242025: 002025

Hospitals counted here

  1. Wuxi No.2 People's Hospital1
  2. Affiliated Hospital of Jiangnan University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Multiple myeloma

多发性骨髓瘤
0.06%Leads under 1 in 100 of China's research papers on Myeloma New since 2021

Led 1 of 1,676 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.8%).

Run this PubMed search

Open trials led
0
Research papers it led
1
Trials it led
1
Share of China's trials
0.2%
Share of the world's papers
0.01%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025
ThemesBispecific & antibody drugs

Hospitals counted here

  1. Affiliated Hospital of Jiangnan University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Idiopathic pulmonary fibrosis

特发性肺纤维化
0.3%Leads under 1 in 100 of China's research papers on Idiopathic pulmonary fibrosis New since 2021

Led 3 of 989 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.3%).

Run this PubMed search

Open trials led
0
Research papers it led
3
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.08%
Papers led per year
2021: 0020212022: 1120222023: 2220232024: 0020242025: 002025

Hospitals counted here

  1. Affiliated Hospital of Jiangnan University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov